Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of California, San Diego
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Arizona
Celldex Therapeutics
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Azienda USL 4 Prato
National Health Research Institutes, Taiwan